<SEC-DOCUMENT>0001193125-24-240148.txt : 20241021
<SEC-HEADER>0001193125-24-240148.hdr.sgml : 20241021
<ACCEPTANCE-DATETIME>20241021114756
ACCESSION NUMBER:		0001193125-24-240148
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		8
CONFORMED PERIOD OF REPORT:	20241021
FILED AS OF DATE:		20241021
DATE AS OF CHANGE:		20241021

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sanofi
		CENTRAL INDEX KEY:			0001121404
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				133529324
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-31368
		FILM NUMBER:		241382444

	BUSINESS ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017
		BUSINESS PHONE:		33153774400

	MAIL ADDRESS:	
		STREET 1:		46 AVENUE DE LA GRANDE ARMEE
		CITY:			PARIS
		STATE:			I0
		ZIP:			75017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI-AVENTIS
		DATE OF NAME CHANGE:	20040826

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANOFI SYNTHELABO SA
		DATE OF NAME CHANGE:	20010104
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d857882d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">For the month of
October 2024 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Commission File Number: <FONT STYLE="white-space:nowrap">001-31368</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>SANOFI </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Translation of
registrant&#146;s name into English) </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">46, avenue de la Grande Arm&eacute;e, 75017 Paris, FRANCE </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">(Address of principal executive offices) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F</FONT> &#9746;&#8195;&#8195;&#8195;Form <FONT
STYLE="white-space:nowrap">40-F</FONT> &#9744; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">In October 2024, Sanofi published the press releases attached hereto as Exhibits 99.1 and 99.2 which are
incorporated herein by reference. </P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center"><B>Exhibit Index </B></P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="89%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; ">Exhibit No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:9pt; font-family:Times New Roman; " ALIGN="center">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="32"></TD>
<TD HEIGHT="32" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d857882dex991.htm">Press Release dated October&nbsp;17, 2024: Sanofi and Orano join forces to develop next-generation radioligand medicines </A></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="49"></TD>
<TD HEIGHT="49" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top" NOWRAP>Exhibit&nbsp;99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d857882dex992.htm">Press Release dated October&nbsp;21, 2024: Sanofi and CD&amp;R partner to fuel Opella&#146;s ambitions in consumer healthcare </A></TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman">SIGNATURES </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:6%; font-size:9pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:9pt">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="37%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top">Dated: October&nbsp;21, 2024</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">SANOFI</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">By&#8195;&#8195;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"><U>/s/ Alexandra Roger&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;&#8195;</U></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Alexandra Roger</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:9pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: Head of Legal Corporate&nbsp;&amp; Finance</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d857882dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="50%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="49%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"><FONT STYLE="font-size:14pt"><B>Press Release</B></FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g857882page1a.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g857882page4b.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="justify"><FONT COLOR="#8925ff"><I>Sanofi and Orano join forces to develop next-generation radioligand medicines
</I></FONT></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Paris, October</B><B></B><B>&nbsp;17, 2024.</B> Sanofi and Orano Med, a subsidiary of the Orano Group and a pioneer in the
development of targeted alphatherapies in oncology, have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the development of next-generation radioligand medicines. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Building on the expertise and radioligand pipeline of Orano Med, Sanofi and Orano will invest in a new entity, operating under the Orano Med brand, and
focusing on the discovery, design, and clinical development of next-generation radioligand therapies (RLTs) based on <FONT STYLE="white-space:nowrap">lead-212</FONT> (<SUP STYLE="font-size:75%; vertical-align:top">212</SUP>Pb) alpha-emitting
isotopes. This agreement follows Sanofi&#146;s announcement of an exclusive licensing agreement with Orano Med and RadioMedix to advance radioligand therapies (RLTs) in rare cancers with a focus on one late-stage project, AlphaMedix<SUP
STYLE="font-size:75%; vertical-align:top">&#153;</SUP>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Targeted alpha therapy relies on a simple concept: combining the ability of biological
vectors to target cancer cells with the short-range and highly energetic cell-killing capabilities of alpha-emitting radioisotopes. The vector directs the radioisotope to the target cancer cells expressing the specific marker, even when they have
spread throughout the body. This unique mechanism of action aims to damage or destroy target cancer cells, while limiting impact on nearby healthy cells. This novel precision medicine approach aims at changing the standard of care in some rare
cancers to extend patients&#146; lives and improve their quality of life. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:9.5pt; font-family:Times New Roman"><FONT COLOR="#8925ff"><B><I>Paul Hudson </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">CEO, Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;We are excited to partner with Orano in establishing a French pioneer that unites our respective
expertise in biopharma and nuclear technology to drive groundbreaking progress in the fight against cancer. As a French biopharmaceutical company, we are deeply committed to fostering and enabling innovation in our home country. This collaboration
is part of a broader effort to strengthen our ties within the scientific community, both in France and globally, with the goal of advancing the development of cutting-edge treatments for patients.&#148;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#8925ff"><B><I>Nicolas Maes </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">CEO, Orano Group </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;The success of Orano Med is an example of our group&#146;s ability to diversify beyond our core
nuclear business. By applying our expertise in nuclear materials to fields like targeted alpha therapies, we are demonstrating that nuclear technology can have a positive societal impact, not just for energy and climate, but also for human health.
This innovation reflects Orano&#146;s commitment to exploring new opportunities and taking bold steps to address some of the world&#146;s most pressing challenges.&#148;</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Sanofi&#146;s investment will further strengthen Orano Med and allow the company to accelerate the development of its pipeline, leveraging its unique
capabilities in the discovery and development of <FONT STYLE="white-space:nowrap">lead-212</FONT> based therapies. Orano Med has also developed a highly differentiating global industrial platform, which, thanks to its vast stock of raw materials and
patented manufacturing process, will ensure an independent, reliable, and scalable supply of <FONT STYLE="white-space:nowrap">lead-212</FONT> based therapies to patients worldwide. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g857882page4c.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"><FONT STYLE="background-color:#cccccc; " COLOR="#2b579a">1</FONT>/<FONT STYLE="background-color:#cccccc; " COLOR="#2b579a">3</FONT></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#8925ff"><B><I>Houman Ashrafian </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Executive Vice President, Head of Research and Development, Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;We are thrilled to invest in the promising field of radioligand therapies, a modality that holds
potential for patients suffering from rare cancers. We see opportunity in the innovative <FONT STYLE="white-space:nowrap">lead-212</FONT> based technologies being developed by Orano Med, which align with our commitment to advancing transformative
therapies for unmet medical needs.&#148;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#8925ff"><B><I>Julien Dodet </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">President of the Governing Board, Orano Med </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:7%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;Sanofi&#146;s partnership with Orano Med is a strong recognition of the potential of <FONT
STYLE="white-space:nowrap">lead-212</FONT> based radioligand therapies to advance the treatment of cancers. This validates our strategy, having developed this expertise over the past 15 years, and reinforces our position as a leader in targeted
alpha therapies. We look forward to combining Sanofi&#146;s expertise with our R&amp;D and world-class radiopharmaceutical capabilities to advance the development of potentially transformative therapies like AlphaMedix and make them available to
patients in need as quickly as possible.&#148;</I> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">In striving to become a leading immunoscience company globally, Sanofi remains committed to
advancing oncology innovation. The pipeline is being reshaped and prioritized, leveraging expertise in immunoscience to drive progress. Efforts are centered on
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">difficult-to-treat</FONT></FONT> cancers such as select hematologic malignancies and solid tumors with critical unmet needs, including rare cancers such as multiple myeloma, acute
myeloid leukemia, and certain types of lymphomas, as well as gastrointestinal and lung cancers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Sanofi and Orano Med are members of the Paris
Saclay Cancer Cluster and look forward to contributing to the ambitious agenda of the France 2030 plan to accelerate innovation in oncology. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">This
agreement is subject to standard regulatory approvals required for transactions of this nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#8925ff"><B><I>Financial considerations
</I></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Under the terms of the agreement, Sanofi will make an equity investment of
<FONT STYLE="font-family:Times New Roman">&#128;</FONT>300&nbsp;million, approximately 16% equity stake in the new entity valued at <FONT STYLE="font-family:Times New Roman">&#128;</FONT>1.9bn. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #999999">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#8925ff"><B><I>About Sanofi </I></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">We
are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible
into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on
EURONEXT: SAN and NASDAQ: SNY </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#8925ff"><B><I>About Orano Med </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">Orano Med, a subsidiary of the Orano Group, is a clinical-stage biotechnology company that develops a new generation of targeted therapies against cancer
using the unique properties of <FONT STYLE="white-space:nowrap">lead-212</FONT> (<SUP STYLE="font-size:75%; vertical-align:top">212</SUP>Pb), an alpha-emitting radioisotope and one of the more potent therapeutic payloads against cancer cells known
as Targeted Alpha-Emitter Therapy (TAT). The company is developing several treatments using <SUP STYLE="font-size:75%; vertical-align:top">212</SUP>Pb combined with various targeting agents. Orano Med has <SUP
STYLE="font-size:75%; vertical-align:top">212</SUP>Pb manufacturing facilities, laboratories, and R&amp;D centers in France and in the US and is currently investing to further expand its <FONT STYLE="white-space:nowrap">GMP-manufacturing</FONT>
capacities for <SUP STYLE="font-size:75%; vertical-align:top">212</SUP>Pb radiolabeled pharmaceuticals in North America and Europe. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">As a recognized
international operator in the field of nuclear materials, Orano Group delivers solutions to address present and future global energy and health challenges. Its expertise and mastery of cutting-edge technologies enable Orano to offer its customers
high value-added products and services throughout the entire fuel cycle. Every day, the Orano group&#146;s 17,500 employees draw on their skills, unwavering dedication to safety and constant quest for innovation, with the commitment to develop <FONT
STYLE="white-space:nowrap">know-how</FONT> in the transformation and control of nuclear materials, for the climate and for a healthy and resource-efficient world, now and tomorrow. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #999999">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g857882page4c.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"><FONT STYLE="background-color:#cccccc; " COLOR="#2b579a">2</FONT>/<FONT STYLE="background-color:#cccccc; " COLOR="#2b579a">3</FONT></TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT COLOR="#8925ff"><B><I>Contacts </I></B></FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Orano Med </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Sophie Letournel</B><B></B>&nbsp;|&nbsp;+33 6 38 44 34
11|<U> </U><U>sophie.letournel@orano.group</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Orano Group </I></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Press Office</B><B></B>&nbsp;|&nbsp;+33 (0)1 34 96 12 15| <U>press@orano.group</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><I>Orano Investor relations </I></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Marc Quesnoy</B> |
<U>investors@orano.group</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT COLOR="#8925ff"><I>Sanofi Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Sandrine Guendoul</B><B></B>&nbsp;|&nbsp;+ 33 6 25 09 14 25 | <U>sandrine.guendoul@sanofi.com</U> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Evan Berland</B> | +1 215 432 0234 | <U>evan.berland@sanofi.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Nicolas
Obrist</B><B></B>&nbsp;|&nbsp;+ 33 6 77 21 27 55 | <U>nicolas.obrist@sanofi.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Victor Rouault</B><B></B>&nbsp;|&nbsp;+ 33 6 70 93 71 40 |
<U>victor.rouault@sanofi.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Timothy Gilbert</B><B></B>&nbsp;|&nbsp;+ 1 516 521 2929 | <U>timothy.gilbert@sanofi.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><FONT COLOR="#8925ff"><I>Sanofi Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Thomas
Kudsk Larsen</B> |+ 44 7545 513 693 | <U>thomas.larsen@sanofi.com</U> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Aliz&eacute; Kaisserian</B><B></B>&nbsp;|&nbsp;+ 33 6 47 04 12 11 |
<U>alize.kaisserian@sanofi.com</U> </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #999999">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL"><B>Sanofi forward-looking statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:7pt; font-family:ARIAL" ALIGN="justify">This press release contains
forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance.
Forward-looking statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148; and similar expressions. Although Sanofi&#146;s
management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are
difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks
and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and
when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product
candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#146;s ability to benefit from external growth opportunities, to complete
related transactions and/or obtain regulatory clearances, risks associated with intellectual property and any related pending or future litigation and the ultimate outcome of such litigation,&nbsp;trends in exchange rates and prevailing interest
rates, volatile economic and market conditions, cost containment initiatives and subsequent changes thereto, and the impact that pandemics or other global crises may have on us, our customers, suppliers, vendors, and other business partners, and the
financial condition of any one of them, as well as on our employees and on the global economy as a whole.&nbsp;The risks and uncertainties also include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by
Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended
December&nbsp;31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL">All trademarks mentioned in this press release are the property of the Sanofi group apart from AlphaMedix. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g857882page4c.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="middle" ALIGN="right"><FONT STYLE="background-color:#cccccc; " COLOR="#2b579a">3</FONT>/<FONT STYLE="background-color:#cccccc; " COLOR="#2b579a">3</FONT></TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>d857882dex992.htm
<DESCRIPTION>EX-99.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Exhibit 99.2 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:14pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:9.5pt">
<TD VALIGN="bottom"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:14pt"><B>Press Release</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">


<IMG SRC="g857882g1021170200023.jpg" ALT="LOGO">
</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:17pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Sanofi and CD&amp;R partner to fuel Opella&#146;s ambitions in consumer healthcare </I></FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Sanofi and CD&amp;R enter exclusive negotiations to transfer a 50% controlling stake in Opella with Sanofi to remain a
significant shareholder </P></TD>
<TD WIDTH="4%">&nbsp;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">With 11,000 talented and passionate people bringing iconic brands to life, Opella poised to ignite new bold development
journey </P></TD>
<TD WIDTH="4%">&nbsp;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Sanofi to become a focused science-driven biopharma delivering innovative medicines and vaccines to patients </P></TD>
<TD WIDTH="4%">&nbsp;</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="justify" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Sanofi 2024 business EPS guidance upgraded today </P></TD>
<TD WIDTH="4%">&nbsp;</TD></TR></TABLE> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify"><B>Paris, October</B><B></B><B>&nbsp;21, 2024. </B>Sanofi and CD&amp;R announce today a plan to join forces to
fuel Opella&#146;s ambitions as a French-headquartered, global consumer healthcare champion. Sanofi and CD&amp;R have entered exclusive negotiations for the potential sale and purchase of a 50% controlling stake in Opella. This new step in
Opella&#146;s journey paves the way for the creation of a new, standalone leader in consumer healthcare, while supporting Sanofi&#146;s strategy and increased focus on innovative medicines and vaccines. Sanofi would remain a significant shareholder
backing Opella in its future growth and path to independence. Together, CD&amp;R and Sanofi will support Opella&#146;s growth strategy as a pure-play, global, and fast-moving consumer healthcare company. Bpifrance is expected to participate as a
minority shareholder with a c.2% stake. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Headquartered in France, Opella employs over 11,000 talented and passionate people, operates in 100
countries with 13 <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">best-in-class</FONT></FONT> and strategic manufacturing sites and four science and innovation development centers. With a portfolio of iconic brands, such as
Allegra, Doliprane, and Dulcolax, Opella is already the third-largest business worldwide in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> and vitamins, minerals&nbsp;&amp; supplements market
(OTC&nbsp;&amp; VMS), serving more than half a billion consumers worldwide. Opella operates in a fast-growing industry driven by sustainable long-term trends, such as an aging population, rising income levels, and greater health and well-being
awareness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The valuation of Opella is based on an enterprise value of c.<FONT STYLE="font-family:Times New Roman">&#128;</FONT>16&nbsp;billion,
corresponding to c.14 times 2024 estimated EBITDA. The offer from CD&amp;R is binding and fully financed. By remaining a significant shareholder in Opella, Sanofi would retain a part of the future value creation of the company. The proposed
transaction is subject to finalization of definitive agreements, completion of the appropriate social processes, and subject to customary statutory approvals. The anticipated closing of the transaction would be in Q2 2025 at the earliest. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">CD&amp;R has a proven track record of partnering with corporates and management teams to support businesses&#146; growth and development, leveraging the
firm&#146;s global reach, deep industry expertise and broad network of operating partners and advisors. CD&amp;R has a long history of investment in Europe and the firm&#146;s experience building French national champions and supporting French jobs
goes back more than twenty years and includes successful partnerships with, and investments in, Rexel, Spie, BUT/Conforama and Socotec. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT
 COLOR="#7a00e6"><B><I>Paul Hudson </I></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Chief Executive Officer, Sanofi </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;We are proud of what Opella and its inspired people have already accomplished. We are confident that
the future of Opella will be even brighter. We share the love and emotional attachment to Opella&#146;s brands, hence our decision to remain vested in its future. We will support Opella on its path to become an independent company, grounded in
talented people, a deep consumer expertise and a truly global presence with deep roots in France. Our chosen partner CD&amp;R has demonstrated unique capabilities in the consumer space, with deep values of respect for employees, customers,
communities in which they operate, and the environment. We also welcome Bpifrance as a supporter of Opella&#146;s development journey. At the same time, Sanofi can focus even more in bringing innovative solutions to patients suffering from
debilitating or life-threatening diseases or viruses such as RSV, COPD, or multiple sclerosis.&#148; </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g857882page0001.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">1/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Eric Rouzier </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">Partner and Head of European Healthcare, CD&amp;R </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;This is an exciting opportunity for CD&amp;R to partner with Sanofi, one of the world&#146;s leading
healthcare companies, to support Opella&#146;s ambitious management team as it invests in innovation and growth to create a French-headquartered, global consumer healthcare champion. Opella is differentiated by the quality of its brand portfolio and
its highly skilled and motivated workforce. We see significant opportunities to enhance Opella&#146;s market leadership by leveraging our deep industry expertise, broad network of operating talents, and capital resources to position the company for
accelerated growth. We look forward to supporting both its French operations, including Opella&#146;s critical manufacturing footprint and advanced R&amp;D capabilities, and further developing its global platform to better serve employees,
consumers, and patients.&#148; </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Julie Van Ongevalle </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:ARIAL" ALIGN="justify">President and Chief Executive Officer, Opella </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; margin-right:4%; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><I>&#147;This announcement is a major and exciting milestone in Opella&#146;s journey. Building on significant
transformations, we have grown into one of the largest global players in our&nbsp;sector, bringing relevant innovation to more than half a billion consumers worldwide. Partnering with CD&amp;R will allow Opella to unlock its full development
potential, to further drive value creation and deploy the exceptional talent of our teams to become a leading company in the fast-moving consumer healthcare space. We are poised to continue leveraging our strong scientific roots to grow our iconic
&#147;love brands&#148; to meet consumers&#146; evolving needs and make self-care as simple as it should be.&#148; </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Accounting treatment </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The proposed transaction will trigger the classification of Opella&#146;s business as discontinued operations. From Q4 2024 and until the closing, the
profit or loss of Opella, net of tax, will be included in &#147;Net results from discontinued operations&#148; in the Sanofi income statement. This classification as discontinued operations will also apply to previous quarters of 2024 and for
comparison to all quarters of 2023. Sanofi <U>business</U> net income<SUP STYLE="font-size:75%; vertical-align:top">1</SUP> used for EPS is based on the continuing operations, i.e., excluding the discontinued Opella business. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Q3 2024 results scheduled for October&nbsp;25, 2024, will be reported as per the past quarters. The income statements with Opella as discontinued
operations for the comparative periods of 2023 and 2024, including details by product and quarter, are expected to be provided in the coming weeks. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">After the closing of the transaction, the share of results from the retained minority interest in Opella will be reported in Sanofi&#146;s income
statement as &#147;Share of profit/loss of associates&#148;, a line that is also excluded from Sanofi&#146;s <FONT STYLE="white-space:nowrap">non-IFRS</FONT> financial measures, business operating income and business net income used for EPS. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">As is customary with similar transactions, Zantac<SUP STYLE="font-size:75%; vertical-align:top">2</SUP> and Gold Bond are excluded from the scope of the
contemplated transaction. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Guidance </I></B></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">The original 2024 business EPS guidance issued on February&nbsp;1, 2024, and upgraded on July&nbsp;25, 2024, anticipated Opella as a fully consolidated
segment in Sanofi for 2024. Under the previous scope of guidance including Opella, Sanofi would have upgraded its 2024 business EPS guidance to between stable to a low single-digit percentage growth at CER<SUP
STYLE="font-size:75%; vertical-align:top">3</SUP>, from previously stable at CER. This upgrade is substantiated by an expected strong business performance in the third quarter that will be detailed as part of Q3 2024 results. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Under the new scope excluding Opella, preliminary business EPS in 2023 was <FONT STYLE="font-family:Times New Roman">&#128;</FONT>7.25. Sanofi expects
its 2024 business EPS to grow by at least a <FONT STYLE="white-space:nowrap">low-single</FONT> digit percentage at CER. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">For 2025, Sanofi continues
to anticipate a strong rebound in business EPS at CER under both the previous and the new scope. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><B><I>Capital allocation
</I></B></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Sanofi expects to receive a cash payment upon the anticipated closing of the transaction in Q2 2025 at the earliest. The proceeds
would be used in line with Sanofi&#146;s existing capital-allocation priorities, including shareholder returns. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:21%">&nbsp;</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify"><SUP
STYLE="font-size:75%; vertical-align:top">1</SUP> <FONT STYLE="white-space:nowrap">Non-IFRS</FONT> measure. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify"><SUP
STYLE="font-size:75%; vertical-align:top">2</SUP> Zantac 360&deg; is included in the scope of the contemplated transaction. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify"><SUP
STYLE="font-size:75%; vertical-align:top">3</SUP> Constant exchange rates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g857882page0001.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">2/3</TD></TR></TABLE>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="justify">Sanofi&#146;s capital-allocation priorities remain unchanged<SUP
STYLE="font-size:75%; vertical-align:top">4</SUP>, including selectively considering external growth opportunities to further accelerate the ongoing transformation into a biopharmaceutical company. Sanofi intends to maintain its current strong debt
credit rating<SUP STYLE="font-size:75%; vertical-align:top">5</SUP>. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #cccccc">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>About Sanofi </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL" ALIGN="justify">We are an
innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people&#146;s lives. Our team, across the world, is dedicated to transforming the practice of medicine by working to turn the impossible into
the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on
EURONEXT: SAN and NASDAQ: SNY. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Media Relations </I></FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Sandrine Guendoul</B><B></B>&nbsp;|&nbsp;+ 33 6 25 09 14 25 | <FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>sandrine.guendoul@sanofi.com</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Nicolas Obrist</B><B></B>&nbsp;|&nbsp;+ 33 6 77 21 27 55
|&nbsp;<FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>nicolas.obrist@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>L&eacute;o Le
Bourhis </B>|&nbsp;+ 33 6 75 06 43 81 | <FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>leo.lebourhis@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Victor Rouault</B><B></B>&nbsp;|&nbsp;+ 33 6 70 93 71 40 | <FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>victor.rouault@sanofi.com</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Evan Berland</B> | +1 215 432 0234 |
<FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>evan.berland@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Timothy
Gilbert</B><B></B>&nbsp;|&nbsp;+ 1 516 521 2929 | <FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>timothy.gilbert@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:9pt; font-family:Times New Roman"><FONT COLOR="#7a00e6"><I>Investor Relations </I></FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Thomas Kudsk
Larsen</B> |+ 44 7545 513 693 | <FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>thomas.larsen@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Aliz&eacute; Kaisserian</B><B></B>&nbsp;|&nbsp;+ 33 6 47 04 12 11 |
<FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>alize.kaisserian@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Arnaud
Del&eacute;pine</B><B></B>&nbsp;|&nbsp;+ 33 6 73 69 36 93 | <FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>arnaud.delepine@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Felix Lauscher</B><B></B>&nbsp;|&nbsp;+ 1&nbsp;908&nbsp;612 7239 |
<FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>felix.lauscher@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Keita
Browne</B><B></B>&nbsp;|&nbsp;+ 1 781 249 1766 | <FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>keita.browne@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Nathalie Pham</B><B></B>&nbsp;|&nbsp;+ 33 7 85 93 30 17 | <FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>nathalie.pham@sanofi.com</U></FONT><FONT
STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Tarik Elgoutni </B>| + 1 617 710 3587 |
<FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>tarik.elgoutni@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:9pt; font-family:ARIAL"><B>Thibaud
Ch&acirc;telet</B> | + 33 6 80 80 89 90 | <FONT STYLE="font-family:ARIAL; font-size:9pt" COLOR="#7a00e6"><U>thibaud.chatelet@sanofi.com</U></FONT><FONT STYLE="font-family:ARIAL"> </FONT></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:4.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #cccccc">&nbsp;</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL"><B>Forward-looking statements </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify">This press release contains
forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their
underlying assumptions, statements regarding plans, business transformations, objectives, intentions, and expectations with respect to future financial results, events, operations, services, product development and potential, and statements
regarding future performance. Forward-looking statements are generally identified by the words &#147;expects&#148;, &#147;anticipates&#148;, &#147;believes&#148;, &#147;intends&#148;, &#147;estimates&#148;, &#147;plans&#148;, &#147;potential&#148;,
&#147;outlook&#148;, &#147;guidance&#148; and similar expressions. Although Sanofi&#146;s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information
and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or
implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, those inherent in research and development, future clinical data and analysis, including post marketing, decisions by
regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application as well as their decisions regarding labelling and other matters that could affect the availability or commercial
potential of such product candidates, the fact that product candidates if approved may not be commercially successful, the future approval and commercial success of therapeutic alternatives, Sanofi&#146;s ability to benefit from external growth
opportunities, to complete capital markets or other transactions, risks associated with developing standalone businesses and with intellectual property, as well as any related pending or future litigation and the ultimate outcome of such litigation,
and other risks&nbsp;associated with trends in exchange and interest rates, volatile economic, political, financial and market conditions, cost containment initiatives, and the impact of pandemics or other global crises may have. More specifically
regarding the transaction described above, these risks and uncertainties include among other things the possibility that the transaction will not be completed, or if completed, will not be completed in the expected timeframe, an unexpected failure
to satisfy the required signing or closing conditions, or unexpected delays in meeting these requirements, the ability to obtain regulatory clearances, the possibility that the expected strategic benefits, synergies or opportunities from the
transaction may not be realized, or may take longer to realize than expected, or potential adverse reactions to the proposed transaction by customers, suppliers, strategic partners or key Sanofi or Opella employees. The risks and uncertainties also
include the uncertainties discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under &#147;Risk Factors&#148; and &#147;Cautionary Statement Regarding Forward-Looking Statements&#148; in
Sanofi&#146;s annual report on Form <FONT STYLE="white-space:nowrap">20-F</FONT> for the year ended December&nbsp;31, 2023. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking
information or statements. All trademarks mentioned in this press release are the property of the Sanofi group. </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:21%">&nbsp;</P> <P STYLE="margin-top:10pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify"><SUP
STYLE="font-size:75%; vertical-align:top">4</SUP> Organic investment, M&amp;A/business development, growing dividend, and anti-dilutive share buybacks. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:ARIAL" ALIGN="justify"><SUP STYLE="font-size:75%; vertical-align:top">5</SUP> Moody A1 (stable) and S&amp;P AA (stable). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">

<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top">


<IMG SRC="g857882page0001.jpg" ALT="LOGO">
</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">3/3</TD></TR></TABLE>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g857882g1021170200023.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g857882g1021170200023.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  I )(# 2(  A$! Q$!_\0
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M>T^'FK:A:Z/;6]U:Q!XI(EVD'<!_6N7_ &>O%^G65A?^';VXC@G>X^T6YD;
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D8)%>^T4 >/Z/\/O$%MHEA!-!"LL5M&CKYHX(4 BBO8** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g857882page0001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g857882page0001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1"  0 #H# 2(  A$! Q$!_\0
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E@!'^O]J]O*^),SRVG*E@:\J<9.[2ZM'9ALPQ.'BXT9N*?8__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g857882page1a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g857882page1a.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  (" @(" @(" @(" @(" @(" @(" @(" @(" @(" @("
M @(" @,# @(# @(" P0# P,#! 0$ @,$! 0$! ,$! ,! @(" @(" @(" @,"
M @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# __$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M]G[7V<O9)VY^5\M^W-:U_F:%<YF% !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 >;?&'XDZ7\'OA=XZ^)VLH9=/\ !/AS4=<E@!V_:9K:+;9VF[^ 3WKV\.[^
M'S<X.,$ _DAD\0_M/?\ !0CXX'1+76=0\0^(M9>_O]/T2?5IM+\'^#M MFWO
MLA0F'3]-M8Y(4:1())I7<$AW<T ?L5_P3W_8"^-/[,_QDU_Q]\4M8\,W>F'P
M=<:)HT7ASQ!J6I_:+_4KNW>Z-W:76GVJQI#!;#:YWG,AP!S1M\@V^1Y?)^SA
M^U(/VF1JQT;Q%)<?\+"76QXY6](T?^R!JXNOM_\ :(GP(1IQ*?9B!(0#%Y>#
MS_?-/Q'\+5X9/"_7\'&BLH>%_LITG]9^L_5W35/V/)\7MK3]KS<OVN:Y^WQX
M@X:7#GLO;T5%87V?U;E_>>TY.7EY>7?GUYKVZW/WMK^!C\0,CQ!KNE>%]"UC
MQ)KEW'8:-H&F7VL:I>2G$=K8:=;27=W,WKMAB<A1R2 !R10!_,-^T;_P5@^/
M7Q&\5ZEH_P $M0D^&7@2&^DLM$;2K.WN?&&N0I*T5O?WVIS0RR64UQPR6MB(
M@H9%8NX)H ^<6_;'_;N\$20ZOJOQ6^,>FPR2+)$_BF/57TR=F(*@0ZY9FVF5
MO[NT@T;!L?KA_P $Y?\ @H%\<OVBOB)+\)OB5X:T?Q)#9>';[7+CX@Z1:KHE
MWIBV)@B@BUFPMD^PW*W4LGEQM!';2;\DB0 [0#[P_;%_:_\ !7[(O@"'Q%K-
MK_PD/C#Q \]EX+\'07 MYM5O($!FOK^<!FLM&M=Z&6;:6<L(H@78M& ?SJ^,
MO^"E/[:7Q2UZ=O#WCC4O#,,CR267AKX=:+%;+:6X;(C$T%M/J%X$! ,EQ/(?
MITH S?#_ /P4B_;9^'^IJFH?$W5]2D@(,^D>.- T[4?,0\;94U*P6YA# $;H
MY$;T((S1M\@V^1_0A^P%^U9XD_:R^$FK>+_%_A_2=!\1>&?$LGAK4/[#:Y&F
M:EML;:^AOH;:[EEDM)&CN LD?FNNY24VJ0  ?F]^V]_P4[^._P ,_C1X\^#O
MPJL_#/A/3O!6HC1G\1W>EQZ[KNHW(M8I;BX5=2,EE:0[I<1JEJ7 7)<FC] _
M0_/AOVY?VZ]?$FL6GQ6^)<]HI:1Y]%TYXM+C"9+973M-%LD:X.1P!B@#Z!_9
M]_X*W?'WP'XETNR^,=[;?$_P'-=0P:NUUIUG8>*M+M)'1)K_ $S5-/@B-[/"
MN7^SWD<PD"E59&8,#8-C^G7PSXCT?Q=X>T3Q3X?NTO\ 1/$.EV6L:3>1XV7%
MC?VZ7-O( "<$QR+E<\$$=J /PS_;8_X*O:[X/\6ZW\*_V;ETKS_#US/I?B'X
ME:C:PZJAU2W9H;RP\,:?<!K62&WE#1O?7"3!G0^2BA=[ 'YIK^WG^W):[/%3
M?%SX@C3FE#I>3Z?&_AUW+\1K'+IIL&0MQL QVQ1L&Q^J'[#G_!5+4?B9XLT;
MX1_M"V^DV/B'7IX]/\+?$'2X(],L-2U63Y;?2?$6FQXM[&YN7PD%W;"*)I"L
M<D:EU<GZ!^A]P?\ !2)WC_8O^-NQBN[1-+1L$C*-X@TK*G'8X'% '\K/P$^+
M_P 9_@OXKOO$OP0O-0L/%%WI$VF7DVF^'[?Q#/\ V5++'),IM+BPNEB3S8XS
MY@12"!\U&P;'[S?\$S?VEOVI/C9\2?'^A_'+4M;U+P]I7A&RU'2_[4\'6OAZ
M*VU-]3\@F*\MM)M#(\EN6!B=W!"9"C!- 'PS-_P46_:W3]I(>"U^)4*^&/\
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M6XO"6CV6A6OB+PQX?\1ZC8:=!':V1UB^AE2_O(K>)52)[AX5ED"  NS$ 9H
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MS:G;V\MQ<&2WE+!8=@7;\Y)P #[)_P""*?\ R0/XE^WQ./X?\4]IE 'XS_\
M!0C_ )/)^/7_ &.DW_I%9T ?U[?"_P#Y)I\//^Q&\)_^F&PH _F6_P""P_\
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8 "@ H * "@ H * "@ H * "@ H * /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g857882page4b.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g857882page4b.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MV9G"M2G*I3A4C*=%J,XIIR@VKKFCNKK576JU6AI"IV^1IMY6%H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * #I^']*-OD&WR/F/XR_M9_"SX%
M>*+/PAXVA\4R:K?:);:_ VB:/!J%H+&ZO+^QB#S2ZC 5G\[3KC*;" I0Y^;
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M_A_4=*T[3]>U#0K>:ZUF^U2TN9-0GTMXKN;RTM87C$=S" P;>)%;;0!]J?\
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MU.=&:O&2:M_78\O\(^)KO1-:/P\\4/MOX%)\/ZI(Y$.K60RT%N'EQNN%CR$
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MEKNM65DM@MS_ ,)!?+I&E64EU+>2HEI8B*"&(SW+W)L&QWM !0 4 % !0 4
M% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
#!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g857882page4c.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g857882page4c.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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MQ7VG?5]K+H?=M?,'FE>0JYDM_,=':+<3&VUT1RT8=&YVL"IP<<'%-:6?1/\
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M2;?9[37,>D&TT &TT &TT &TT &TT &TT &TT . Q_GTH 6@ H * "@ H *
B"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
